Geode Capital Management LLC Makes New $171,000 Investment in Palvella Therapeutics (NASDAQ:PVLA)

Geode Capital Management LLC purchased a new position in Palvella Therapeutics (NASDAQ:PVLA - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,270 shares of the company's stock, valued at approximately $171,000. Geode Capital Management LLC owned 0.13% of Palvella Therapeutics at the end of the most recent reporting period.

Separately, BML Capital Management LLC purchased a new position in shares of Palvella Therapeutics during the fourth quarter worth approximately $506,000. 40.11% of the stock is currently owned by institutional investors.

Insider Activity

In other Palvella Therapeutics news, Director George M. Jenkins bought 2,500 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, April 9th. The shares were bought at an average cost of $20.13 per share, with a total value of $50,325.00. Following the transaction, the director now directly owns 183,171 shares of the company's stock, valued at approximately $3,687,232.23. This represents a 1.38 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 6.39% of the company's stock.

Analyst Ratings Changes

Several research analysts recently issued reports on PVLA shares. Scotiabank assumed coverage on Palvella Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $38.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, April 30th. Chardan Capital assumed coverage on shares of Palvella Therapeutics in a research note on Wednesday, April 9th. They issued a "buy" rating and a $50.00 price objective for the company. Jones Trading started coverage on shares of Palvella Therapeutics in a report on Tuesday, March 25th. They set a "buy" rating and a $45.00 target price on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Palvella Therapeutics in a report on Wednesday, March 26th. They issued a "buy" rating and a $45.00 price target for the company. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $44.43.

Palvella Therapeutics Price Performance

NASDAQ:PVLA traded down $0.07 during midday trading on Friday, reaching $22.97. 3,746 shares of the stock traded hands, compared to its average volume of 69,887. The company has a market cap of $253.66 million, a PE ratio of -1.90 and a beta of 0.10. Palvella Therapeutics has a 12-month low of $6.20 and a 12-month high of $29.27. The firm has a 50-day moving average price of $24.86.

Palvella Therapeutics Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.